| Primary | Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC) | MCC was the volume instilled into the bladder prior to leakage or end of bladder-filling (whichever was reached first), as assessed by urodynamics (procedure: the bladder was to be filled until voiding/leakage began, or until it was stopped because either the participant experienced pain or discomfort or 135% of expected bladder capacity [EBC] was reached for participants ≥ 2 years or of maximum catheterized volume [MCV] for participants aged 6 months to < 2 years; the participants' bladder was emptied via catheterization). | Full Analysis Set (FAS), which consisted of all participants who took at least one dose of study drug and provided both valid baseline and at least one post-baseline value for the primary efficacy endpoint. | Posted | | Mean | Standard Deviation | mL | | Baseline and Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| | | Title | Denominators | Categories |
|---|
| | |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | t-test, 2 sided | | <0.001 | From a 2-sided one sample t-test, testing the null hypothesis that change from baseline = 0. | | | | | | | | | | | | | Other | | |
|
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12 and 52 in MCC | MCC was the volume instilled into the bladder prior to leakage or end of bladder-filling (whichever was reached first) as assessed by urodynamics (procedure: the bladder was to be filled until voiding/leakage began, or until it was stopped because either the participant experienced pain or discomfort or 135% of EBC was reached for participants ≥ 2 years or of MCV for participants aged 6 months to < 2 years. The participants' bladder was emptied via catheterization). | FAS population with available data at baseline and at each time point. | Posted | | Mean | Standard Deviation | mL | | Baseline and Weeks 3, 6, 9, 12, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Compliance | Bladder compliance gives an indication of the elasticity of the bladder wall. Bladder compliance was calculated by dividing the change in volume during the filling of the bladder by the change in detrusor pressure during that change in bladder volume using urodynamic assessments. The values for bladder volume and detrusor pressure at the beginning and end of filling were taken and used. | FAS population with available data at baseline and at each time point. | Posted | | Mean | Standard Deviation | mL/cmH2O | | Baseline and Weeks 3, 6, 9, 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure at End of Bladder-Filling | Detrusor pressure was expressed as bladder pressure minus intra-abdominal pressure as assessed by urodynamics. | FAS population with available data at baseline and at each time point. | Posted | | Mean | Standard Deviation | cmH2O | | Baseline and Weeks 3, 6, 9, 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure 5 Minutes After End of Bladder-Filling | Detrusor pressure was expressed as bladder pressure minus intra-abdominal pressure as assessed by urodynamics. | FAS population with with available data at baseline and at each time point. | Posted | | Mean | Standard Deviation | cmH2O | | Baseline and Weeks 3, 6, 9, 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Catheterized Volume 5 Minutes After End of Bladder-Filling | Catheterized volume was measured when the bladder was emptied via catheterization 5 minutes after the end of bladder-filling. | FAS population with available data at baseline and at each time point. | Posted | | Mean | Standard Deviation | mL | | Baseline and Weeks 3, 6, 9, 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume Until First Detrusor Contraction (> 15 cmH2O) | Bladder volume as assessed by urodynamics. | FAS population with data available at baseline and at each time point and excluding participants who did not have a detrusor contraction. | Posted | | Mean | Standard Deviation | mL | | Baseline and Weeks 3, 6, 9, 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 10 cmH20 Detrusor Pressure | Bladder volume as assessed by urodynamics. | FAS population with data available at baseline and at each time point and whose pressure reached 10 cmH2O. | Posted | | Mean | Standard Deviation | mL | | Baseline and Weeks 3, 6, 9, 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 20 cmH20 Detrusor Pressure | Bladder volume as assessed by urodynamics. | FAS population with data available at baseline and at each time point and whose pressure reached 20 cmH2O. | Posted | | Mean | Standard Deviation | mL | | Baseline and Weeks 3, 6, 9, 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 30 cmH20 Detrusor Pressure | Bladder volume as assessed by urodynamics. | FAS population with data available at baseline and at each time point and whose pressure reached 30 cmH2O. | Posted | | Mean | Standard Deviation | mL | | Baseline and Weeks 3, 6, 9, 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Number of Overactive Detrusor Contractions (> 15 cmH2O) Until Leakage or End of Bladder-Filling | | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | contractions | | Baseline and Weeks 3, 6, 9, 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average Catheterized Volume Per Catheterization | The average catheterized volume per catheterization was calculated using all available (non-zero) catheterized volumes recorded over both of the 2 measuring days in the diary, whether or not these 2 days were concurrent. Catheterized volumes were recorded for 2 days in a participant diary prior to each visit. Four to six catheterizations were performed every day. | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | mL | | Baseline and Weeks 3, 6, 9, 12, 24, 36, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Maximum Catheterized Volume (MCV) | The maximum catheterized volume per day was calculated using all available (non-zero) catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days were concurrent. The maximum value was calculated separately for each measuring day and the mean of these two values was used. | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | mL | | Baseline and Weeks 3, 6, 9, 12, 24, 36, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average First Morning Catheterized Volume | The first morning catheterized volume was the volume associated with the first morning catheterization. The average first morning catheterized volume was calculated as the average of the available first morning catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days are concurrent. | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | mL | | Baseline and Weeks 3, 6, 9, 12, 24, 36, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Mean Number of Periods Between the Clean Intermittent Catheterizations (CICs) With Incontinence Per 24 Hours | Participants were required to have 4-6 CICs per day on a schedule fixed for the duration of the study. To calculate the number of periods between CICs with incontinence in a diary day, the diary day was divided into periods between CICs (i.e. inter-CIC periods). The hour period, rather than the exact time, of each CIC and incontinence episode was recorded in the diary. When an incontinence episode and a CIC were marked in the same hour period, the incontinence episode was counted as occurring prior to the CIC (when the bladder had not yet emptied), rather than after it (when the bladder had recently been emptied), i.e. the inter-CIC period ended with the hour in which the CIC was recorded. The mean number of periods between CICs with incontinence per 24 hours was the number of periods between CICs when incontinence occurred, divided by the total number of valid diary days. | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | periods | | Baseline and Weeks 3, 6, 9, 12, 24, 36, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Catheterizations for Each Hour of 24 Hour Day at Baseline | For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with catheterization | | 3 days prior to Baseline visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 3 | For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with catheterization | | 3 days prior to Week 3 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 6 | For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with catheterization | | 3 days prior to Week 6 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 9 | For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with catheterization | | 3 days prior to Week 9 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 12 | For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with catheterization | | 3 days prior to Week 12 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 24 | For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with catheterization | | 3 days prior to Week 24 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 36 | For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with catheterization | | 3 days prior to Week 36 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 52 | For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all subjects. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with catheterization | | 3 days prior to Week 52 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Incontinence for Each Hour of 24 Hour Day at Baseline | Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with incontinence | | 3 days prior to Baseline visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With of Incontinence for Each Hour of 24 Hour Day During Week 3 | Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with incontinence | | 3 days prior to Week 3 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 6 | Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with incontinence | | 3 days prior to Week 6 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 9 | Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with incontinence | | 3 days prior to Week 9 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 12 | Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with incontinence | | 3 days prior to Week 12 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 24 | Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with incontinence | | 3 days prior to Week 24 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 36 | Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with incontinence | | 3 days prior to Week 36 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 52 | Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. | | Posted | | Number | | percentage of days with incontinence | | 3 days prior to Week 52 visit | Days | Days | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Week 24 and 52 in Infant and Toddler Quality of Life Short Form-47 Questionnaire (ITQoL SF-47) - Overall Health Score | The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). | FAS population with available data at baseline and at each time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline and Weeks 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Physical Abilities Score | The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline and Weeks 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Growth and Development Score | The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline and Weeks 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Pain Score | The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline and Weeks 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Temperament and Moods Score | The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline and Weeks 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Behaviour Score | The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline and Weeks 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Week 24 and 52 in ITQoL SF-47 - General Health Score | The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline and Weeks 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Change in Health Score | The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline and Weeks 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Emotional Impact Score | The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline and Weeks 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Time Impact Score | The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline and Weeks 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |
| Secondary | Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Family Cohesion Impact Score | The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). | FAS population with data available at baseline and at each time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline and Weeks 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Solifenacin Succinate | Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods. |
| |